InsiderPulse| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-17 | 2026-02-17 | Nassif Mikheal | Director & CEO | Purchase | 23 | $10.94 | $251.62 | 704 | View ↗ |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Revenues | $97.3M-4.9% | $102.4M-4.6% | $107.4M+4.8% | $102.5M | — |
| Cost of Revenues | $61.8M+4.4% | $59.2M-4.1% | $61.8M+10.1% | $56.1M | — |
| Cost of Revenues | $61.8M+4.4% | $59.2M-4.1% | $61.8M+10.1% | $56.1M | — |
| Gross Profit | $421.4M-9.2% | $463.9M+14.3% | $406.0M+67.1% | $243.0M | — |
| Sales and marketing | $183.8M+0.5% | $182.9M+29.5% | $141.2M+66.9% | $84.6M+15.2% | $73.4M |
| General and administrative | $218.2M+9.1% | $199.9M-0.6% | $201.2M+143.1% | $82.7M+61.6% | $51.2M |
| Goodwill impairment | $1.06B | $0 | $0 | — | — |
| Research and development | $21.1M-6.2% | $22.5M-13.7% | $26.0M+52.7% | $17.0M+4.9% | $16.2M |
| Total Operating Expenses | $1.48B+265.8% | $405.2M+10.0% | $368.4M+99.8% | $184.4M+30.9% | $140.9M |
| Operating Loss (Income) | -$1.06B-1908.6% | $58.7M+56.4% | $37.5M | — | — |
| Interest income | $3.1M-51.1% | $6.4M+100.9% | $3.2M+136.4% | $1.3M-20.9% | $1.7M |
| Interest expense | -$71.6M+2.4% | -$73.4M-31.2% | -$56.0M-77623.6% | -$72K+7.7% | -$78K |
| Other, net | -$3.6M+39.3% | -$5.9M+12.2% | -$6.8M-2200.0% | $322K+162.5% | -$515K |
| Total Other Expense | -$72.1M+1.2% | -$73.0M-22.5% | -$59.6M | — | — |
| Loss Before Taxes | -$1.13B-7821.1% | -$14.3M+35.1% | -$22.0M | — | — |
| Income Tax (Benefit) Expense | -$41.1M-740.8% | -$4.9M-689.9% | $828K-93.0% | $11.9M | — |
| Net Loss | -$1.09B-11491.6% | -$9.4M+58.8% | -$22.9M | — | — |
| Basic | $216.89B+0.2% | $216.48B+14.6% | $188.88B+75.4% | $107.68B+101012.7% | $106.5M |
| Diluted | $216.89B+0.2% | $216.48B+14.6% | $188.88B+74.9% | $108.02B+100740.2% | $107.1M |
| Basic | $216.89B+0.2% | $216.48B+14.6% | $188.88B+75.4% | $107.68B+101012.7% | $106.5M |
| Diluted | $216.89B+0.2% | $216.48B+14.6% | $188.88B+74.9% | $108.02B+100740.2% | $107.1M |
| Product Revenues | |||||
| Total Revenues | $97.3M-4.9% | $102.4M-4.6% | $107.4M+4.8% | $102.5M | — |
| Cost of Revenues | $61.8M+4.4% | $59.2M-4.1% | $61.8M+10.1% | $56.1M | — |
| Cost of Revenues | $61.8M+4.4% | $59.2M-4.1% | $61.8M+10.1% | $56.1M | — |
| Service Revenues | |||||
| Total Revenues | $97.3M-4.9% | $102.4M-4.6% | $107.4M+4.8% | $102.5M | — |
| Cost of Revenues | $61.8M+4.4% | $59.2M-4.1% | $61.8M+10.1% | $56.1M | — |
| Cost of Revenues | $61.8M+4.4% | $59.2M-4.1% | $61.8M+10.1% | $56.1M | — |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Is Weaker Sales And Returns Reshaping The Investment Case For Neogen’s (NEOG) Valuation Assumptions?
1 of Wall Street’s Favorite Stock to Target This Week and 2 Facing Challenges
3 Reasons NEOG is Risky and 1 Stock to Buy Instead
Neogen’s Listeria Right Now™ Test Receives AOAC® Performance Tested Methods℠ Certification